India, July 9 -- Shares of Evoke Pharma, Inc. (EVOK) gained over 163% on Wednesday morning after the specialty pharmaceutical company announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a U.S. patent application covering the use of GIMOTI in patients with moderate to severe symptoms of gastroparesis.
EVOK is currently trading at $7.02, up $4.36 or 163.75%, on a large volume of 65.2 million shares, above average volume of 15 thousand, on the Nasdaq. The stock opened its trading at $8.42 after closing Tuesday at $2.66. The stock has traded between $1.94 and $12.32 in the past 52-week period.
The allowed application is a continuation of U.S. Patent No. 11,517,545, and further expands Evoke's int...